Clearside Biomedical, Inc. / Fundamentals
Income statement
- Net revenue
€3.59M - Cost of goods sold
€414.41K - Gross profit
€3.17M - SG&A expenses
€9.65M - R&D expenses
€12.42M - EBITDA
-€15.61M - D&A
€278.28K - EBIT
-€18.83M - Interest expenses
€9.02M - EBT
-€23.26M - Tax expenses
€616.01K - Net income
-€23.88M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€2.95M - Changes in working capital
-€2.66M - Operating cash flow
-€18.72M - Capex
€428.19K - Other investing cash flow
€6.45M - Net investing cash flow
€9.35M - Total cash dividends paid
€0.00 - Issuance of common stock
-€1.96M - Debt repayment
€841.73K - Other financing cash flow
-€895.15K - Net financing cash flow
€1.74M - Foreign exchange effects
€0.00 - Net change in cash
-€7.64M - Cash at end of period
€8.08M - Free cash flow
-€18.29M
Balance sheet
- Cash and cash equivalents
€8.08M - Cash and short-term investments
€8.08M - Total receivables
€703.02K - Inventory
€0.00 - Other current assets
€1.37M - Total current assets
€10.15M - Property, plant & equipment
€3.03M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€25.85K - Total non-current assets
€3.06M - Total assets
€13.21M - Accounts payable
€972.69K - Short-term debt
€328.25K - Other current liabilities
€1.32M - Total current liabilities
€2.63M - Long-term debt
€261.91K - Deferred tax liabilities
€0.00 - Other non-current liabilities
€52.44M - Total non-current liabilities
€52.57M - Total liabilities
€55.20M - Common stock
€67.20K - Retained earnings
-€317.04M - Other equity
€0.00 - Total equity
-€41.99M - Total liabilities and shareholders' equity
€13.21M
Company information
- Market capitalization
€51.04M - Employees
32 - Enterprise Value
€49.79M
Company ratios
- Gross margin
-
88.5% Much better than peer group: -1,491,792,535,330.3% - EBITDA margin
-
-435.0% Much better than peer group: -3,528,836,040,002.4% - EBIT margin
-
-524.6% Much better than peer group: -3,731,597,618,187.1% - EBT margin
-
-648.0% Much better than peer group: -3,580,897,917,454.4% - Net margin
-
-665.2% Much better than peer group: -3,580,897,917,386.6% - ROE
-
56.9% Much better than peer group: -48.9% - ROA
-
-180.7% Much worse than peer group: -43.9% - Asset turnover
-
27.2% Much better than peer group: 6.6% - FCF margin
-
-533.4% Much better than peer group: -2,983,258,111,590.4% - FCF yield
-37.5% - Efficiency ratio
535.0% - Net sales per employee
-
€112.16K - Net income per employee
-
-€746.10K